Skip to main content

Table 1 Characteristics of the eligible studies

From: Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials

Study name

Publication

Year

Phase

Blind

Stage

Sample size (n)

Treatment

Experiment

Control

Experiment

Control

ASCEND-4 [12]

Lancet

2017

III

open-label

III, IV

189,187

Ceritinib 750 mg/day

Pemetrexed 500 mg/ m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5–6

PROFILE 1014 [7, 25]

NEJM, JCO

2014, 2018

III

open-label

III, IV, recurrent

172,171

Crizotinib 250 mg bid

Pemetrexed 500 mg/ m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5–6

ALEX [10, 26]

NEJM, Ann Oncol

2017, 2020

III

open-label

III, IV

152,151

Alectinib 600 mg bid

Crizotinib 250 mg bid

ALTA-1 L [11, 27]

NEJM, JCO

2018, 2020

III

open-label

III, IV

137,138

Brigatinib 180 mg/day after a 7-day lead-in period of 90 mg/day

Crizotinib 250 mg bid

eXalt3 [13, 28]

WCLC, JAMA Oncology

2020, 2021

III

open-label

III, IV

143,147

Ensartinib 225 mg qd

Crizotinib 250 mg bid

J-ALEX [29,30,31]

Lancet, Lung cancer, ASCO

2017, 2019, 2021

III

open-label

IIIB, IV, recurrent

103,104

Alectinib 300 mg bid

Crizotinib 250 mg bid

PROFILE 1029 [32]

JTO

2018

III

open-label

III, IV, recurrent

104,103

Crizotinib 250 mg bid

Pemetrexed 500 mg/ m2 plus cisplatin 75 mg/m2 or carboplatin AUC 5–6

ALESIA [33]

Lancet Respir Med

2019

III

open-label

IIIB, IV

125 62

Alectinib 600 mg bid

Crizotinib 250 mg bid

CROWN [34]

NEJM

2020

III

open-label

III, IV

149,147

Lorlatinib 100 mg qd

Crizotinib 250 mg bid

  1. AUC, Area Under Curve; NEJM, New England Journal Medicine; JCO, Journal of Clinical Oncology; Ann Oncol, Annals of Oncology; WCLC, World conference on lung cancer; ASCO, American Society of Clinical Oncology congress; JTO, Journal of Thoracic Oncology; Lancet Respir Med, The Lancet Respiratory Medicine